Will newer tyrosine kinase inhibitors have an impact in AML?

Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA.
Best practice & research. Clinical haematology (Impact Factor: 2.12). 12/2010; 23(4):489-94. DOI: 10.1016/j.beha.2010.09.008
Source: PubMed


FLT3 inhibition has been a goal of acute myeloid leukemia (AML) therapy since FLT3 mutations were discovered to have a role in AML. Several FLT3 inhibitors have been developed in the last several years, beginning with less potent, less selective agents. The newer FLT3 inhibitors appear to be more potent in vivo and have shown more promise than the older agents in monotherapy trials.

Full-text preview

Available from:
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Acute myeloid leukemia with a FLT3 internal tandem duplication (FLT3/ITD) mutation is an aggressive hematologic malignancy with a generally poor prognosis. It can be successfully treated into remission with intensive chemotherapy, but it routinely relapses. At relapse, the blasts tend to have higher mutant allelic ratios and, in vitro, are more addicted to the aberrant signaling from the FLT3/ITD oncoprotein. They remain highly responsive to FLT3 ligand, the levels of which rise several-fold during the course of chemotherapy. The question now arises as to whether these high levels of FLT3 ligand are actually promoting relapse, and, if so, how we can use this information to adjust our therapeutic approach and improve the cure rate for acute myeloid leukemia with FLT3/ITD.
    Preview · Article · May 2011 · Blood
  • [Show abstract] [Hide abstract]
    ABSTRACT: Small molecule inhibitors of protein kinases have emerged as a major class of therapeutic agents for the treatment of hematological malignancies. Both in vitro studies and patient case reports suggest therapeutic potential of the clinical kinase inhibitors erlotinib and gefitinib in acute myeloid leukemia (AML). The drugs' cellular modes of action in AML warrant further investigation as their primary therapeutic target, the epidermal growth factor receptor, is not expressed. We therefore performed SILAC-based quantitative mass spectrometry analyses to a depth of 10,975 distinct phosphorylation sites to characterize the phosphoproteome of KG1 AML cells and its regulation upon erlotinib and gefitinib treatment. Less than 50 site-specific phosphorylations changed significantly, indicating rather specific interference with AML cell signaling. Many drug-induced changes occurred within a network of tyrosine phosphorylated proteins that included Src family kinases (SFKs) and the tyrosine kinases Btk and Syk. We further performed quantitative chemical proteomics in KG1 cell extracts and identified SFKs and Btk as direct cellular targets of both erlotinib and gefitinib. Taken together, our data suggest that cellular perturbation of SFKs and/or Btk translates into rather specific signal transduction inhibition, which in turn contributes to the antileukemic activity of erlotinib and gefitinib in AML.
    No preview · Article · Nov 2011 · Journal of proteomics
  • [Show abstract] [Hide abstract]
    ABSTRACT: The FMS-like receptor tyrosine kinase-3 (FLT3) plays a key role in hematopoietic development and is frequently mutated in patients with acute myeloid leukemia (AML). These mutations render FLT3 constitutively active, and patients harboring these mutations have a poor prognosis. Targeting the kinase activity of FLT3 with inhibitory compounds is therefore an attractive therapeutic option. Over the last few years, numerous FLT3 inhibitors have undergone clinical trials. Although some have been disappointing, some newer agents have shown promise. This review provides an overview of FLT3 signaling, recent progress with next-generation inhibitors, and unexpected hurdles encountered when combining FLT3 inhibitors with chemotherapy.
    No preview · Article · Jan 2012 · Critical reviews in oncogenesis
Show more